Artemisia annua has been used by Chinese herbalists for more than two thousand years in the treatment of many illnesses, such as skin diseases and malaria. The earliest record dates back to 200 BC, in the "Fifty-two Prescriptions" unearthed from the Mawangdui Han Dynasty tombs. Its antimalarial application was first described, in Zhouhou Beiji Fang ("The Handbook of Prescriptions for Emergencies"), edited in the middle of the fourth century by Ge Hong. In that book, 43 malaria treatment methods were recorded.
For many years after the discovery, access to the purified drug and the plant from which it was extracted were restricted by the Chinese government. It was not until the late 1970s and early 80s that news of the discovery reached scientists outside China. The World Health Organisation (WHO) tried to contact Chinese scientists and officials to find out more, but drew a blank. Ying Lee, one of the scientists involved in the research into artemisinin, said the Chinese distrusted the West. The Chinese suspected the West just wanted to exploit the drug and sell it around the world slightly altered and repatented. The fact that there were several Americans on the WHO's steering board on malaria and that some were from the military did not help clear the distrust. It can be noted Americans had just invested a lot into mefloquine, an analogue of quinine.
In 2006, after artemisinin had become the treatment of choice for malaria, the WHO called for an immediate halt to single-drug artemisinin preparations in favor of combinations of artemisinin with another malaria drug, to reduce the risk of parasites developing resistance.
In 2011, Tu was awarded the prestigious Lasker-DeBakey Clinical Medical Research Award for her discovery. The discovery of artemisinin is reportedly being considered for a Nobel Prize in Medicine.
Project 523 developed, in addition to artemisinin, a number of products that are used in combination with artemisinin, including lumefantrine, piperaquine, and pyronaridine.
Read More: artemisinin price
No comments:
Post a Comment